On Tuesday, Geron Corporation (NASDAQ:GERN)’s shares inclined 2.45%, and closed at $3.76, as Geron Corporation (GERN), declared that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the corporation at the 14th Annual Needham Healthcare Conference in New York. The presentation is planned to occur on Tuesday, April 14, at 5:00 p.m. Eastern Time.
Geron Corporation, a clinical stage biopharmaceutical corporation, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has partnership and license contract with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, counting hematologic myeloid malignancies and other human therapeutic uses. The corporation was founded in 1990 and is based in Menlo Park, California.
LinnCo LLC (NASDAQ:LNCO)’s shares raised 2.35%, and settled at $10.87, during the last trading session on Tuesday, as LinnCo LLC (LNCO) and LINN Energy, LLC (LINE), stated that administration will host a conference call on Wednesday, April 29, 2015, at 10 a.m. Central (11 a.m. Eastern) to talk about the Corporation’s first quarter 2015 results. Prepared remarks by Mark E. Ellis, Chairman, President and Chief Executive Officer, and Kolja Rockov, Executive Vice President and Chief Financial Officer, will be followed by a question and answer session.
LinnCo, LLC, through its limited liability corporation interests in Linn Energy, LLC, focuses on the attainment and development of oil and natural gas properties in the United States. The corporation was founded in 2012 and is headquartered in Houston, Texas.
At the end of Tuesday’s trade, VeriFone Systems Inc (NYSE:PAY)’s shares picked up 2.33%, and closed at $35.19, soon after VeriFone Systems (PAY), declared that TransFirst®, a leading provider of transaction processing services and payment enabling technologies, has certified Verifone’s Secure Commerce Architecture (SCA).
Certification of SCA enables TransFirst and its merchants, financial institutions and independent sales organizations (ISOs) to connect Verifone’s EMV and NFC-enabled VX 520 payment terminal and VX 805 PIN pad directly to TransFirst’s web-based payment processing platform — Transaction Express®.
VeriFone Systems, Inc. designs, markets, and services electronic payment solutions at the point of sale (POS) worldwide. It provides countertop electronic payment systems that accept card payment options, such as NFC, mobile wallets, chip and PIN, and contactless payments, in addition to support credit and debit card, EBT, EMV, and other PIN-based transactions; and a portfolio of application libraries and development tools.
Cytori Therapeutics Inc (NASDAQ:CYTX), ended its Tuesday’s trading session with 2.27% gained, and closed at $1.35, as Cytori Therapeutics (CYTX), declared that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has designated Cytori’s ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma. This designation marks the first autologous adipose derived cell therapy for scleroderma granted orphan status in the European Union (EU).
Cytori is presently working with leading scleroderma centers in France led by the Assistance Publique des Hôpitaux de Marseille to start a 40 patient EU pivotal trial called SCLERADEC-II. The trial is a follow-up controlled trial to the first SCLERADEC trial published last August (Granel et al. Annals of the Rheumatic Diseases, 2014). If successful, this trial would potentially lead to EMA approval of Cytori’s lead therapeutic for this indication in the EU, as an ATMP or Advanced Therapy Medicinal Product.
Cytori Therapeutics, Inc., a biotechnology corporation, develops cell therapeutics for specific diseases and medical conditions. The corporation primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
